If a patient of advanced NSCLC, no targetable driver mutation is found and PD-L1 expression is ≥ 50%, which of the following will be the best treatment approach

Q. If a patient of advanced NSCLC, no targetable driver mutation is found and PD-L1 expression is ≥ 50%, which of the following will be the best treatment approach :

A.            Pembrolizumab

B.            Pembrolizumab plus single agent platinum

C.            Pembrolizumab plus platinum based doublet chemotherapy

D.            Platinum based doublet chemotherapy

Answer: Pembrolizumab